Posted by AGORACOM-JC
at 7:00 PM on Sunday, November 15th, 2020
The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.
Plant Based Essentials …. Like Chocolate (Essential? You Bet)
And …… Plant Based …. PLANTS (It’s A BIG Business!)
More than just talk, VEGA is already in full swing and growing FAST
Already Operating In Canada
US Online Operations Kick Off With $USD 25M MIN of PlantX products YEAR 1
6% Royalty Fee to PlantX on gross USA revenues
US Bricks & Mortar with San Diego flagship store opening in DECEMBER
Agreement already signed with a major construction company to build the flagship + franchises across North America
AND ….. The recent £8 million Acquisition of Bloombox In The UK, generating millions in revenue
If you believe in the paradigm shifting nature of plant based foods and more, be sure to watch and share this great interview with PlantX CEO Julia Frank.
Posted by AGORACOM-JC
at 12:18 PM on Thursday, November 12th, 2020
The devastation and destruction of Coronavirus COVID-19 is well documented and doesn’t need much repeating here.
What we do know is that COVID-19 has created global demand for highly specialty products required to protect, test, detect and defend as many people as possible.
Moreover, given its persistence and the potential for a 2nd wave around the world, governments and businesses both big and small are now in need of solutions that go beyond locking down economies by helping them stay open, generate revenue, keep people employed … all while keeping them safe.
There are no magic bullets. COVD-19 didn’t exist 12 months ago, so there are no established or incumbent leaders. This has created an opportunity for small but nimble companies with high-tech expertise to adapt their products as solutions in one of the many verticals that require help fighting COVID-19.
Here are 6 small-cap companies (in alphabetical order) that have provided real solutions to helping the fight against COVID-19.
Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC )an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution. When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.
Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions. This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.
REVENUE $CAD
Q1 + 62% To $809,000
Q2 + 419% To $1,954,000
TOTAL Q1 AND Q2
REVENUE $2.8M vs $875K = +220%
GROSS PROFIT $1.2 vs $739K = +62%
Given the speed of incoming contracts, the quarterly financials don’t reflect deals done during the third quarter. Here’s just a few;
Datametrex Expands Distribution of Film and Television Coronavirus Testing Across Canada (October 27, 2020)
Expands to Toronto Film Production Company for COVID-19 Testing Solutions (September 30, 2020)
$20M Supply Agreement With Major Worldwide Media & Entertainment Company for COVID-19 (September 24, 2020)
Received Third COVID-19 Order from TV Production Company (September 21, 2020)
Received COVID-19 Test Kits Order for $1.6M From a Canadian Mining Company (September 3, 2020)
·· The company has also experienced robust demand for related services. Datametrex entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure (RPA) in order to automate certain business processes.
The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process.
For more information, please visit the Datametrex AI hub on AGORACOM.
Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for …. but that’s not all. In an effort to combat COVID-19 the company’s physician staffed clinics have are also generating significant revenue and growth as follows:
Increased CBD treatments from patients suffering increased anxiety;
Covid-19 Testing for individuals and families
Covid-19 Testing for local businesses and employees
Covid-19 Testing for enterprise level organizations across the country
Empower Clinics and Loop Insights Combine COVID-19 Testing Expertise With Venue Tracing To Create First Ever “Travel Bubble” Solution For Global Travel Industry Set To Lose $3.3 Trillion
How significant is this acquisition that only closed a couple of weeks ago? At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY.
Patient Visits
Q1 + 377% To 5,717
Q2 + 56% To 6,696
Revenues $USD
Q1 + 416% To $790,000 (NO COVID)
Q2 + 56% To $923.000
TOTAL Q1 AND Q2
REVENUE $1.7M vs $745K = + 130%
PATIENTS 12,400 vs 5,500 = + 125%
NET LOSS $920K vs 1.85M = – 50%
Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.
Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never. Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.
For more information about the company, please check out the Empower HUB on AGORACOM.
Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is an Israeli based company developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.
Innocan, together with Tel Aviv University are developing new, revolutionary exosome based technology (CLX), loaded with cannabidiol (CBD) targeting the coronavirus infected lung cells.
Why is this significant?
CLX may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. It is expected to be administrated by inhalation, CLX will be tested on a variety of lung infections focusing on patients infected by the coronavirus disease.
Superior Management Team
More than just lip service, Innocan has a world class management team to make this happen.
In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself. The Innocan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:
Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
While the Company develops their pharmaceutical solution, Innocan has a portfolio of patent-pending and launch ready consumer health products that are already commercializing around the world as follows:
CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.
Global Manufacturing / Distribution Agreements
To support this global growth, Innocan already has the following relationships in place:
Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.
Kontrol Energy is the Google NEST of smart building technology, with a Blue Chip client base to prove it with the likes of Beyond Meat, Toyota, Oxford, Telus and Brookfield to name a few.
As a result, Kontrol is already achieving commercial success as follows:
· Q1 $2.3M
· Q2 $2.7M
TOTAL Q1 AND Q2
REVENUE $5M
GROSS PROFIT $2.7M
ADAPTING CORE TECH TO PROVIDE BLUE CHIP CUSTOMERS WITH REAL-TIME AIR DETECTION OF COVID-19 IN COMMERCIAL BUILDINGS
As a result of the COVID-19 pandemic and the needs of its blue chip customer base, Kontrol is adapting its core technologies team to development and commercialize its Kontrol BioCloud® analyzer, a wall-mounted technology which detects the presence of COVID-19 in the air of commercial buildings and triggers an alert system to provide real time notifications.
GEARING UP PRODUCTION FOR UP TO 20,000 UNITS PER MONTH
Initial expectations, based on lab testing completed to date, is that BioCloud will be effective in small to medium space settings with 3 or more people, and therefore would be suitable for areas such as classrooms, offices, airplanes, trains, buses, long-term care facilities and hospitals. The company is currently building a global supply chain with the goal of being able to supply 20,000 units per month.
The implications of the Kontrol BioCloud® analyzer could be enormous and could have a major impact on the global economy. Paul Ghezzi, CEO of Kontrol Energy has received calls from interested parties spanning the entire globe. In addition, mainstream media has taken notice:
Early tests suggest new Canadian technology could detect the coronavirus in the air Read More
Canadian firm develops tech to ‘detect COVID-19 in the air’; stock doubles Read More.
Kontrol Energy’s BioCloud Featured By Singapore’s IBI Times Read More
CSA APPROVAL RECEIVED ON NOVEMBER 5TH
On Novebmer 5th, KNR announced receipt of CSA standards approval for its BioCloud® technology.
“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”
UL STANDARDS APPROVAL RECEIVED NOVEMBER 12TH
“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”
DISCLAIMER: The Company has not made any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
For more information about the company, please check out the Kontrol Energy hub on AGORACOM.
Loop Insights (MTRX:TSXV)(RACMF:OTCQB) was already a leading provider of contactless solutions and artificial intelligence (“AI”) to the brick and mortar space prior to the arrival of COVID-19.
Over the last few months Loop has adapted its contactless platform to also provide contact tracing and real-time testing to large venues and businesses. More than just lip service, Loop has already announced significant partnerships and news with the likes of:
“By partnering with innovative and leading IoT development companies, such as Loop, we’re ensuring that our customers have access to some of the most advanced IoT business solutions in the world.”
The presentation ended at approximately 1:15 PM EST, and by 8:00 PM EST Loop had received over 100 direct inquiries from enterprise-level attendees spanning many different industries and countries. Loop Insights anticipates many more direct inquiries to be received in the coming days.
Loop Insights CEO Rob Anson:
“We knew going into the webinar that interest in our Contactless Platform and Solutions was very high given the high-level nature of clients we had already announced leading up to it. These attendees, many of whom represent household name entities, were looking to us for solutions that can protect people, instill confidence in their customers and get their enterprises moving once again. Nonetheless, the response to the demonstration of our Contactless Venue Tracing Platform was simply incredible and even surpassed our expectations. We are optimistic that Loop Insights is establishing an identity as a global force in the contactless space and believe the responses will lead to significant business for Loop. We can’t thank Amazon Web Services enough for their continued support and partnership.”
In addition to these successes, Loop stated that its Venue Tracing platform is clearly gaining recognition and third-party validation, including implementations with:
Implemented Into the Las Vegas flagship properties of a Global Hospitality company (July 23, 2020)
Invited by NCAA DIV 1 BIG EAST CONFERENCE To Present Solution For 11 schools (August 17, 2020)
Partnership with BDG sports to deliver NBA, NHL, NCAA and PGA Sporting Events. (August 13, 2020)
Loop Insights Signs $1,930,000 USD License Deal with Austin, TX Based CasaPerks (September 28, 2020)
Selected as the Premier Venue Tracing and Fan Engagement Solution for NCAA College Basketball “Bubble” in Las Vegas (October 8, 2020)
For more information about the company, please check out the Loop Insights hub on AGORACOM.
Primo Nutraceuticals, a player in the hemp space pivoted early in the pandemic to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category. The company further solidified its move to PPE by entering into agreement with Duquette Consulting LLC, a company owned by Dan Duquette.
Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers (https://en.wikipedia.org/wiki/Dan_Duquette). Dan Duquette has joined forces with Primo Nutraceuticals to partner in the development, sourcing and the global supply of personal protective equipment products.
The company has been issued a Medical Device Establishment License from Health Canada.The MDEL is a license issued to companies for the activities of manufacturing, importing and distributing of all four classes of medical devices for human use in Canada. These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few.
The PPE Distribution Market worth $28.9 Billion by 2025 in North America and E.U
The North America and Europe distribution market for PPE is expected to reach US$28.95 M by 2025.
The safety-supplies sector in North America is anticipated to witness significant growth of over 7% from 2017 to 2025.
Head, eye and face protection are anticipated to grow at a compound annual growth rate of over 6% from 2017 to 2025.
For more information about the company, please check out the Primo Nutraceuticals hub on AGORACOM.
Thanks for reading and discovering these great small cap companies. Please be sure to visit the AGORACOM Small Cap Coronavirus Covid-19 company gateway often to stay up to date with new companies at:
Posted by AGORACOM-JC
at 10:28 AM on Thursday, November 12th, 2020
Announced that it has signed a binding letter of intent (“LOI”) with Full Spectrum Biosciences Inc.(“FSB”),a Colorado company
FSB is an intellectual property (“IP”), formulation and white label provider that has conducted sales via e-commerce, online, Amazon and doctors’ offices within the United States offering popular CBD, CBG and Hemp oil extract products like RehabRx and Hemp Pops
The Company will be acquiring the assets and inventory of FSB. The LOI is legally binding and subject to the negotiation of a definitive agreement
VANCOUVER, British Columbia, Nov. 12, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF ) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (” PRIMO ” or the “Company”) is pleased to announce that it has signed a binding letter of intent (“LOI”) with Full Spectrum Biosciences Inc.(“FSB”),a Colorado company.
FSB is an intellectual property (“IP”), formulation and white label provider that has conducted sales via e-commerce, online, Amazon and doctors’ offices within the United States offering popular CBD, CBG and Hemp oil extract products like RehabRx and Hemp Pops. The Company will be acquiring the assets and inventory of FSB. The LOI is legally binding and subject to the negotiation of a definitive agreement (the “ Definitive Agreement ”).
TERMS OF THE TRANSACTION
The Company will acquire 100% of the revenue generating assets including the web sites for the popular CBD, CBG and Hemp oil extract products like RehabRx, ( www.rehabrx.com ) and Hemp Pops, ( www.hemppops.com ), the current inventory and the sales and distribution networks that have generated approximately $25,000 to $30,000 USD in monthly revenues since 2018 (the “Transaction”). Gross margin is estimated at 30%.
The consideration for the Purchase will be stipulated in the form of a number of common shares of PRIMO (the “Consideration Shares”) at a per share price equal to the volume weighted average price of such shares on the Canadian Securities Exchange over a 15-day period ending on the day such Consideration Shares are required to be issued (“15 day VWAP”). The consideration paid by Primo to FSB for the Transaction shall be based on an independent valuation of the Assets by a Third Party Valuator. The valuation is currently in progress.
There will be no Change of Control or Fundamental change of business. The Transaction will be subject to review by the parties’ tax, corporate, and legal advisors prior to Closing. The senior management team of PRIMO will consist of those officers presently appointed by the board of directors of PRIMO and shall remain the same.
AboutAgritekHoldings Inc. and Full Spectrum Biosciences
FSB is a licensed Colorado Corporation which is a wholly owned subsidiary of Agritek Holdings Inc. existing under the laws of the State of Delaware as a “C” corporation, and a publicly traded company on the OTC Markets under the symbol “AGTK” (“Agritek”).
Agritek Holdings, Inc. ( www.AgritekHoldings.com ), is a fully integrated, active real estate investor and advisor of white label brands in the legal cannabis sector. Specifically, Agritek Holdings provides strategic capital and functional expertise to accelerate the commercialization of its diversified portfolio of cannabis related real estate holdings. The hemp based raw material and products produced at facilities owned by Agritek Holdings and leased back to licensed operators are then used for retail branded CBD, CBG and Hemp oil extract products produced by its subsidiary Full Spectrum Biosciences presently sold via e-commerce, online, Amazon and Doctors offices within the United States. Brands include RehabRX, Hemp Pops, MDVapes , and multiple white labeled brands. Agritek Holdings Inc. does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act
“REHAB RX” – Pain Cream, Tinctures, and Gummies; www.rehabrx.com
Rehabrx.com and Hemppops.com are owned and operated by Full Spectrum Biosciences, Inc., a Colorado corporation with offices in Colorado.
The GlobalCBD Market
The global CBD market is expected to reach USD 146.4 billion by the end of 2025, according to a new report by Grand View Research, Inc. Growing adoption of marijuana in several medical applications such as cancer, mental disorders, chronic pain and others is expected to propel revenue growth in near future.
RichardCindric,CEOComments:
“We are extremely excited to be signing a LOI with Full Spectrum. Gaining FSB’s IP, formulation, white label resources as well as it’s already developed brands like RehabRx and Hemp Pops is a major milestone for the company. As we enter the US nutraceutical market with this acquisition, we believe FSB’s assets compliments our nutraceutical line of products very well. We look forward to working with the FSB team, as well as the introduction of possible future acquisitions.”
Michael Friedman, CEO of Full Spectrum Comments:
“I am pleased to deliver on our promise to the Agritek shareholders that our wholly owned subsidiary Full Spectrum Biosciences has entered into this asset purchase agreement with Primo Nutraceuticals. By having access to both the Canadian and US public markets through Primo, we can work to build our company in both jurisdictions and bring greater value through our combined management teams and contacts for our wellness brands. Our recently announced test pilot program with Biomedican (www.Biomedican.com) using proprietary yeast for synthetic cannabinoid profiles in my opinion will propel our combined companies to an entirely different level within the nutraceutical space and allow us to compete as a biotech within the wellness sector under our new parent company Primo Nutraceuticals”, stated B. Michael Friedman, CEO Agritek Holdings Inc.”
About PrimoNutraceuticalsInc.
Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’smanagement is in the process of building a corporate road map to further vertically integrate the Company; specifically, by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.
On behalf of the Board of Directors
PRIMO NUTRACEUTICALS INC.
Richard Cindric CEO and Director
For further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; [email protected] .
To learn more about what this news means to the shareholders visit:
FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.
Posted by AGORACOM-JC
at 9:21 AM on Thursday, November 12th, 2020
There is no denying the world of esports was already on a rapid growth rate prior to the COVID-19 pandemic. However, according to TGS Esports (TGS:TSXV), the growth and awareness of esports over the past several months has accelerated the industry by at least a couple of years, if not more.
Recognizing this trend, TGS pivoted quickly from venue based esports to becoming a leader in esports events, sponsorship and productions. More than just lip service, tournaments hosted to date have been sponsored by the likes of:
Pepsi
Red Bull
7-11
Shaw Cable
More than just events, TGS also creates high quality production value out of these events, which have already seen more than 20,000 hours of viewership on Twitch and featured on GINX Esports TV (Canada), with the potential to expand with GINX to over 50 countries.
If the story ended there, TGS would have the makings of a great early stage esports story …. but it doesn’t
$6 MILLION ACQUISITION OF “PEPPER ESPORTS”
The recent acquisition of Pepper Esports takes the TGS offering to a whole different level by providing everyone from enterprise sized clients to small business to a group of buddies to create their own esports tournaments. The platform is so powerful it will handle everything from registration to game play, prize payouts and everything in between that an entity needs to host a successful esports tournament. Awesome right? No, it gets better.
Hosting your own esports tournament is FREE. TGS and Pepper figured out that the best way to get mass usage of their platform is to make it $0 upfront and generate $$ from revenue share on all transactions that take place during the tournament.
When you bolt on the fact that TGS can now broadcast that tournament, the Company believes its offering can’t be matched anywhere in the world. We like it so much that we’re already considering hosting Agoracom esports tournaments for clients and shareholders who can either play or watch.
Watch this great interview with the CEO’s of both TGS and Pepper to find out more details and feel their mutual excitement about the future.
Posted by AGORACOM-JC
at 8:14 AM on Thursday, November 12th, 2020
Kontrol BioCloud a Safe Space Technology™
Received UL standards approval for its BioCloud® technology
As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.
“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”
TORONTO, ON / November 12, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received UL standards approval for its BioCloud® technology. As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.
“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”
Field Certification was provided by ESAFE
Underwriters’ Laboratories or UL regulations require manufacturers of products sold in the United States to receive UL Standards approval for electrical safety.
ESAFE is accredited by the Standards Council of Canada (SCC), as an Inspection Body (ISO 17020) and Certification Body (ISO 17065). As an accredited agency, ESAFE is authorized to approve and label equipment for electrical safety.
BioCloud® is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud® has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others
BioCloud® is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
For further information, contact:
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp., 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer (BioCloud®) are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Posted by AGORACOM-JC
at 7:39 AM on Thursday, November 12th, 2020
Announced that its Cubeler Lending Hub commercial lending platform has facilitated the first transactions related to a program created by the Company and consumer electronics wholesale distributor Beijing Dianjing Company Ltd. (“BDC”) to bring financing solutions to BDC’s 60,000 online retail clients
Newly-created purchase order financing program allows BDC’s clients, who collectively sell about CAD$50B worth of consumer electronics per year, to have up to 90% of the price of the products they purchase financed by any bank or lending institution represented on the Lending Hub.
Purchase orders for iPhones totalling a combined 48M RMB (about CAD$9.5M) coming from four JD.com (www.jd.com) affiliated stores were the first orders approved for funding through the program
\Montreal, Quebec–(November 12, 2020) – Peak Positioning Technologies Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that its Cubeler Lending Hub commercial lending platform has facilitated the first transactions related to a program created by the Company and consumer electronics wholesale distributor Beijing Dianjing Company Ltd. (“BDC”) to bring financing solutions to BDC’s 60,000 online retail clients.
The newly-created purchase order financing program allows BDC’s clients, who collectively sell about CAD$50B worth of consumer electronics per year, to have up to 90% of the price of the products they purchase financed by any bank or lending institution represented on the Lending Hub.
Purchase orders for iPhones totalling a combined 48M RMB (about CAD$9.5M) coming from four JD.com (www.jd.com) affiliated stores were the first orders approved for funding through the program. The platform collected a fee equivalent to 2% of the annualized interest rate charged by the lender to finance the orders. The financing program was expected to start in early December, but pressing demand from the stores led Peak and BDC to take special measures to allow for these first transactions to be processed while the program is still undergoing minor adjustments.
“Our market research showed that there would be strong demand from online retailers for Lending Hub’s services, but we weren’t expecting to have to start the program almost a full month ahead of schedule,” commented Peak Group China CEO, Mr. Liang Qiu. “Retailers continuously buy and sell inventory and thus have an ongoing need for credit, a need that wasn’t properly addressed until today. We created a program that uses AI and analytics to help retailers buy more products from wholesalers, and are working with some of the country’s largest wholesale distributors to expand it nationwide. I think we have a unique opportunity here to positively impact a large segment of China’s CAD$6.5 trillion annual retail market. This is yet another way in which we believe we can accelerate the proliferation of the Lending Hub to every part of the country.”
About Peak Positioning Technologies Inc.:
Peak Positioning Technologies Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://peakfintechgroup.com/.
For more information, please contact:
CHF Capital Markets Cathy Hume, CEO 416-868-1079 ext.: 251 [email protected]
Peak Positioning Technologies Inc. Johnson Joseph, President and CEO 514-340-7775 ext.: 501 [email protected]
This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.
Posted by AGORACOM-JC
at 7:31 AM on Thursday, November 12th, 2020
Will be presenting at this year’s virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST), and will host virtual one-on-one meetings with interested investors throughout the conference, which runs November 16 -18.
NEW YORK, NY / November 12, 2020 / MedX Health Corp. (“MedX”, or the “Company”) (TSXV:MDX), a Company focused on becoming the leader in teledermatology, will be presenting at this year’s virtual Fall Investor Summit on Tuesday, November 17th at 4:00PM (EST) / 1:00PM (PST), and will host virtual one-on-one meetings with interested investors throughout the conference, which runs November 16 -18. To register, or to schedule a virtual one-on-one meeting, visit https://investorsummitgroup.com/.
During the presentation, MedX’s CEO, Robert von der Porten, and Mike Druhan, President, Dermatology Products & Services, will provide an overview of the Company’s fully integrated telemedicine platform specializing in dermatology and how its platform is being deployed to revolutionize skin cancer detection methods.
The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.
ABOUT MEDX:
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy™ is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
ABOUT THE INVESTOR SUMMIT:
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE
Posted by AGORACOM-JC
at 5:04 PM on Wednesday, November 11th, 2020
SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.
Cannabis-based products or the medical marijuana has orchestrated new avenues in the pharmaceuticals industry
Pharma companies, small and big, have plowed investments in cannabidiol (CBD), particularly
The inroad made by CBD and CBD-based products is unarguably daunting, riding on the wave of staggered legalization of marijuana
The game-changing potential that cannabis has made pharma companies nurse new aspirations by setting their sights in the cannabis pharmaceuticals market
Unsurprisingly, some pharma companies for instance, Insys Therapeutics, put robust opposition to legalization of marijuana. The regulatory status on the CBD is markedly unclear and lack worldwide consensus, for instance, differs from state to state in the U.S., and from nation to nation. Nonetheless, over the years there is a clear surge in interest of pharma companies in medical marijuana, given the medical conditions where cannabis hold incredible potential.
FDA-approved CBD-based drugs will stridently see an increase, expanding the horizon in the CBD market. One of the most recalcitrant diseases CBD-based products in cannabis pharmaceuticals market hold potential, as body of preclinical studies have reiterated, is Dravet syndrome and Lennox-Gastaut syndrome (LGS).
A new study on the cannabis pharmaceuticals market scrutinizes the investment potential of some of the aforementioned trends and the ways in which those will shape the growth dynamics during 2020 – 2030.
Cannabis Pharmaceuticals Market: Key Trends
The shape of the cannabis pharmaceuticals market is expected to be molded by the changing dynamic of the regulatory landscape. A large part of negative public perception of cannabis products has been associated with the recreational use of TSH, a key psychoactive element of cannabis. However, as things have begun to change, the global medicinal industry will intensify its efforts in harnessing therapeutic benefits of cannabis.
The cannabis pharmaceutical industry will see new vistas opening up from expanding array of studies that will provide scientific backing of CBD. This is particularly in relation to the safety and uncontested claims of safety. Further, as regulators will treat different categories of cannabis-based product differently and suitably, the risk benefit profile of cannabis pharmaceuticals will become clearer. The scientific rigor for evidence-based medicine will expand the potential of the market and pave way for research in purified cannabidiol.
Two areas where the industry nurses tall hopes in the cannabis pharmaceuticals market are in reducing opioid epidemic, and in managing some of the hard-to-treat conditions such as some cancers. Stakeholders also appreciate the potential of medical cannabis for aesthetic and medical dermatology.
Cannabis Pharmaceuticals Market: Competitive Analysis and Key Developments
The cannabis pharmaceuticals market has seen numerous big shot companies testing new waters in medical marijuana, and making strategic moves to this end. Research units of a few top pharma companies have made moves toward commercializing cannabinoids for medical use. A recent example is research being made by Avicanna for Johnson & Johnson, and by Vapium for Grenco Science.
Another company, notably a spin-off of Abbott Laboratories, AbbVie Inc. has upped its cannabis-related patents. These developments will undoubtedly strengthen the pipeline of cannabis-related drugs, unlocking new prospects in the cannabis pharmaceuticals market. In the course of time, more start-up companies will ramp up their efforts in patenting Cannabis-based tablets and products.
Another behemoth that is making giant stride in the cannabis pharmaceuticals market is Teva Pharmaceuticals. The company recently announced formally that it has entered into distribution deal with cannabis company Canndoc.
North America has seemed to garner incredible revenue potential among all key geographies in the cannabis pharmaceutical market over the past several years. The groundswell of interest in medical marijuana is circumscribed by favorable regulations in some quarters, notably in parts of the U.S. Intense discussion among industry stakeholders about the taxing and labelling of cannabis-based medicinal products will cement the potential of the regional market. They are keen on increasing the profitability of marijuana-based products. Another promising region is Europe, expanding on the back of rise in investments by pharma companies in CBD.
Posted by AGORACOM-JC
at 9:00 AM on Wednesday, November 11th, 2020
Peter Pascali sits down with AGORACOM to discuss the significance of the Company’s recently closed $12,000,000 financing and its implications on the future of PyroGenesis, including:
The impending uplist to the TSX big board
Potential spin-outs
Reasons for raising more funds than “needed”
What role, if any, potential Iron Ore Pelletization contracts played in the financing
Posted by AGORACOM-JC
at 9:11 AM on Tuesday, November 10th, 2020
Further to its press release dated November 3, 2020, the closing of its bought-deal short form prospectus offering pursuant to which the Company issued 3,354,550 units of the Company (at a price of $3.60 per Unit for aggregate gross proceeds of $12,076,380 (the “ Offering ”), including the full exercise of the over-allotment option
The Offering was led by Mackie Research Capital Corporation, as sole underwriter and sole bookrunner
Net proceeds from the Offering will be used for working capital and other purposes as described in the prospectus of the Company dated November 3, 2020 prepared in connection with the Offering.
MONTREAL, Nov. 10, 2020 — PyroGenesis Canada Inc. (“ PyroGenesis ” or the “ Company ”) (TSXV:PYR) (OTCQB:PYRNF) (FRA:8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and products, is pleased to announce, further to its press release dated November 3, 2020, the closing of its bought-deal short form prospectus offering pursuant to which the Company issued 3,354,550 units of the Company (the “ Units ”) at a price of $3.60 per Unit for aggregate gross proceeds of $12,076,380 (the “ Offering ”), including the full exercise of the over-allotment option. The Offering was led by Mackie Research Capital Corporation, as sole underwriter and sole bookrunner, (the “ Underwriter ”).
Each Unit is comprised of one common share of the Company (a ” Common Share “) and one-half of one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a ” Warrant “). Each Warrant entitles the holder thereof to purchase one additional Common Share at an exercise price of $4.50 for a period of 24 months from the closing of the Offering.
Provided that if, at any time prior to the expiry date of the Warrants, the volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the “ Exchange ”), or other principal exchange on which the Common Shares are listed, is greater than $6.75 for 20 consecutive trading days, the Company may, within 15 days of the occurrence of such event, deliver a notice to the holders of Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice (the “ Accelerated Exercise Period ”). Any unexercised Warrants shall automatically expire at the end of the Accelerated Exercise Period.
The net proceeds from the Offering will be used for working capital and other purposes as described in the prospectus of the Company dated November 3, 2020 prepared in connection with the Offering.
In consideration for the services provided by the Underwriter, the Company has paid a cash commission equal to 6.5% of the gross proceeds of the Offering and issued to the Underwriter an aggregate of 191,414 non-transferable compensation options, which are exercisable into Units at a price of $3.60 per Unit at any time up to 24 months from closing of the Offering.
About PyroGenesis Canada Inc.
PyroGenesis Canada Inc., a high-tech company, is a leader in the design, development, manufacture and commercialization of advanced plasma processes and products. The Company provides its engineering and manufacturing expertise and its turnkey process equipment packages to customers in the defense, metallurgical, mining, advanced materials (including 3D printing), and environmental industries. With a team of experienced engineers, scientists and technicians working out of its Montreal office and its 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. The Company’s core competencies allow PyroGenesis to provide innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. PyroGenesis’ operations are ISO 9001:2015 and AS9100D certified. For more information, please visit www.pyrogenesis.com .
For further information, please contact:
Rodayna Kafal, Vice President, Investor Relations and Strategic Business Development,
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the intended use of the proceeds of the Offering. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s ongoing filings with the securities regulatory authorities, including under “Risk Factors” in the Company’s most recent annual information form, which filings can be found under the Company’s profile at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the Toronto Stock Exchange nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.
